ExpreS2ion co-author of article demonstrating that human antibodies from RH5 vaccine block binding to blood cells
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that a scientific article, documenting that human antibodies against the RH5 protein can stop the malaria parasite from entering human blood cells, has been published in the highly renowned journal Cell. The article is based on a clinical study conducted by researchers at the University of Oxford together with a consortium of research entities including ExpreS2ion.The clinical study was a part of a clinical trial in Oxford of the first vaccine that targets the RH5 malaria protein in a phase I/IIa study. The study was led by researchers